Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

419 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry.
Saladini F, Giammarino F, Maggiolo F, Ferrara M, Cenderello G, Celesia BM, Martellotta F, Spagnuolo V, Corbelli GM, Gianotti N, Santoro MM, Rusconi S, Zazzi M, Castagna A; PRESTIGIO Study Group. Saladini F, et al. Among authors: rusconi s. Int J Antimicrob Agents. 2023 Mar;61(3):106737. doi: 10.1016/j.ijantimicag.2023.106737. Epub 2023 Jan 25. Int J Antimicrob Agents. 2023. PMID: 36708743
Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors.
Rusconi S, La Seta Catamancio S, Citterio P, Kurtagic S, Violin M, Balotta C, Moroni M, Galli M, d'Arminio-Monforte A. Rusconi S, et al. Antimicrob Agents Chemother. 2000 May;44(5):1328-32. doi: 10.1128/AAC.44.5.1328-1332.2000. Antimicrob Agents Chemother. 2000. PMID: 10770770 Free PMC article.
Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA).
Di Vincenzo P, Rusconi S, Adorni F, Vitiello P, Maggiolo F, Francisci D, Di Biagio A, Monno L, Antinori A, Boeri E, Punzi G, Perno CF, Callegaro A, Bruzzone B, Zazzi M; Antiretroviral Resistance Cohort Analysis (ARCA) Collaborative Group. Di Vincenzo P, et al. Among authors: rusconi s. HIV Med. 2010 Sep;11(8):530-4. doi: 10.1111/j.1468-1293.2009.00819.x. Epub 2010 Mar 8. HIV Med. 2010. PMID: 20236364 Free article.
European guidelines on the clinical management of HIV-1 tropism testing.
Vandekerckhove LP, Wensing AM, Kaiser R, Brun-Vézinet F, Clotet B, De Luca A, Dressler S, Garcia F, Geretti AM, Klimkait T, Korn K, Masquelier B, Perno CF, Schapiro JM, Soriano V, Sönnerborg A, Vandamme AM, Verhofstede C, Walter H, Zazzi M, Boucher CA; European Consensus Group on clinical management of tropism testing. Vandekerckhove LP, et al. Lancet Infect Dis. 2011 May;11(5):394-407. doi: 10.1016/S1473-3099(10)70319-4. Epub 2011 Mar 21. Lancet Infect Dis. 2011. PMID: 21429803 Free article. Review.
A novel methodology for large-scale phylogeny partition.
Prosperi MC, Ciccozzi M, Fanti I, Saladini F, Pecorari M, Borghi V, Di Giambenedetto S, Bruzzone B, Capetti A, Vivarelli A, Rusconi S, Re MC, Gismondo MR, Sighinolfi L, Gray RR, Salemi M, Zazzi M, De Luca A; ARCA collaborative group. Prosperi MC, et al. Among authors: rusconi s. Nat Commun. 2011;2:321. doi: 10.1038/ncomms1325. Epub 2011 May 24. Nat Commun. 2011. PMID: 21610724 Free PMC article.
Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.
Di Biagio A, Prinapori R, Giannarelli D, Maggiolo F, Di Giambenedetto S, Borghi V, Penco G, Cicconi P, Francisci D, Sterrantino G, Zoncada A, Monno L, Capetti A, Giacometti A; ARCA Collaborative Group. Di Biagio A, et al. J Antimicrob Chemother. 2013 Jan;68(1):200-5. doi: 10.1093/jac/dks339. Epub 2012 Aug 21. J Antimicrob Chemother. 2013. PMID: 22915463
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy.
Meini G, Rossetti B, Bianco C, Ceccherini-Silberstein F, Di Giambenedetto S, Sighinolfi L, Monno L, Castagna A, Rozera G, D'Arminio Monforte A, Zazzi M, De Luca A; ICONA Foundation Group. Meini G, et al. J Antimicrob Chemother. 2014 Mar;69(3):735-41. doi: 10.1093/jac/dkt426. Epub 2013 Oct 23. J Antimicrob Chemother. 2014. PMID: 24155059 Free PMC article.
Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance.
Madeddu G, De Socio GV, Ricci E, Quirino T, Orofino G, Carenzi L, Franzetti M, Parruti G, Martinelli C, Vichi F, Penco G, Dentone C, Celesia BM, Maggi P, Libertone R, Bagella P, Di Biagio A, Bonfanti P; C.I.S.A.I. Group, Italy. Madeddu G, et al. Int J Antimicrob Agents. 2015 Mar;45(3):289-94. doi: 10.1016/j.ijantimicag.2014.10.013. Epub 2014 Nov 13. Int J Antimicrob Agents. 2015. PMID: 25476452
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study.
Mussini C, Lorenzini P, Cozzi-Lepri A, Lapadula G, Marchetti G, Nicastri E, Cingolani A, Lichtner M, Antinori A, Gori A, d'Arminio Monforte A; Icona Foundation Study Group. Mussini C, et al. Lancet HIV. 2015 Mar;2(3):e98-106. doi: 10.1016/S2352-3018(15)00006-5. Epub 2015 Feb 6. Lancet HIV. 2015. PMID: 26424550
419 results